ARCHIVES

Phase II Elotuzumab Study Demonstrates 33 Months PFS

This article is from The Cancer Letter archive.

Vol. 36 No. 7 | July 26, 2013

Download PDF Visit The Full Archive

Related Articles

Senate Passes Biomedical Research Extension; Could Go to President before Congress Recesses

July 26, 1985

GM Honors Blackburn, Kuhl, Phelps, Speizer, And Willett

June 8, 2001

Low Adiponcetin Hormone Levels Linked to Increased Cancer Risk

January 25, 2013

Genetics Research Is Prevalent In Central Europe as Scientists Seek Answers To Related Questions

August 16, 1991

UICC Seeks Nominations for Mucio Athayde Prize.

January 7, 2000

FDA To Issue “Complete Response” Letters To Drug Sponsors.

July 11, 2008